×
Harrow Common Stock Net 2010-2025 | HROW
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Harrow common stock net from 2010 to 2025. Common stock net can be defined as the value of common equity ownership.
View More
Harrow Common Stock Net 2010-2025 | HROW
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Harrow common stock net from 2010 to 2025. Common stock net can be defined as the value of common equity ownership.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$70.1B
Zoetis (ZTS)
$68.6B
Takeda Pharmaceutical (TAK)
$47.3B
Daiichi Sankyo, - (DSNKY)
$46.4B
BeOne Medicines - (ONC)
$33.9B
Sandoz Group AG (SDZNY)
$27.3B
Summit Therapeutics (SMMT)
$20B
Merck (MKKGY)
$16.3B
Shionogi (SGIOY)
$14.6B
United Therapeutics (UTHR)
$13.9B
Neurocrine Biosciences (NBIX)
$13.6B
Orion OYJ (ORINY)
$11.3B
IPSEN (IPSEY)
$11.1B
Madrigal Pharmaceuticals (MDGL)
$9.4B
Eisai (ESAIY)
$9.2B
Corcept Therapeutics (CORT)
$7.3B
Grifols, S.A (GRFS)
$6.8B
Ionis Pharmaceuticals (IONS)
$6.7B
Stevanato Group S.p.A (STVN)
$6.6B
Ono Pharmaceutical (OPHLF)
$5.7B
Hikma Pharmaceuticals Plc (HKMPF)
$5.4B
Soleno Therapeutics (SLNO)
$3.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.9B
Crinetics Pharmaceuticals (CRNX)
$2.9B
NewAmsterdam Pharma (NAMS)
$2.8B
Hypermarcas (HYPMY)
$2.8B
Catalyst Pharmaceuticals (CPRX)
$2.4B
Centessa Pharmaceuticals (CNTA)
$2.2B
Ocular Therapeutix (OCUL)
$2.1B
Dyne Therapeutics (DYN)
$1.9B